Japan Cardiac Surgery Instruments Market Size

Japan Cardiac Surgery Instruments Market size was valued at USD 141.3 million in 2024 and is anticipated to surpass USD 357.1 million by the end of 2036, expanding at a CAGR of 8% during the forecast period, i.e., 2025-2036. In 2025, the industry size of japan cardiac surgery instruments is evaluated at USD 151.7 million.

The growth of Japan cardiac surgery instruments market is attributed to the increasing incidence of cardiovascular diseases, which is attributed to the growing geriatric population and altered lifestyle. Due to the population of 36 million people over 65 years, the need for sophisticated surgical treatment of cardiovascular diseases is rising in Japan. This trend drives competition and cooperation between medical device makers to create new products to support minimally invasive and robotic surgical procedures. In March 2024, Japan Lifeline signed an agreement with Meril Life Sciences to launch the Myval transcatheter heart valve in Japan, reflecting an increasing interest in minimally invasive heart procedures.

The government of Japan has been working closely to develop healthcare facilities to enhance the development of cardiac surgery. As stated by the Ministry of Health, Labour, and Welfare of Japan, medical device development and an increased number of cardiac centers are key drivers of japan cardiac surgery instruments market growth. Terumo Cardiovascular Systems, in July 2024, launched a USD 42 million manufacturing facility in Costa Rica to produce high-precision components for cardiopulmonary bypass systems for Japan and other regions. Such initiatives keep Japan at the forefront of cardiovascular treatment and enhance the country's healthcare industry.